drugset / Trial / NCT01852019

Cangrelor Prasugrel Transition Study

NCT01852019

Phase 2 Completed 12 enrolled The Medicines Company
RandomizedSingle-groupOpen-label

Summary

To demonstrate that patients treated with cangrelor can be directly switched to oral prasugrel and that patients treated with prasugrel can be switched to cangrelor without a significant decrease in the extent of inhibition of platelet aggregation.

Timeline

Start
2013-06
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cangrelor Small molecule 4 ug/kg Intravenous
Subject Prasugrel Small molecule 10 mg Oral